Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin’s lymphoma: a systemic review and meta-analysis-Reference-Cited by-同舟云学术

Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin’s lymphoma: a systemic review and meta-analysis

Published:2018-11-27 Issue:1 Volume:24 Page:199-207
ISSN:1607-8454
Container-title:Hematology
language:en
Short-container-title:Hematology

Author:

Yu Jian¹²,Wang Wen¹²,Huang He¹²

Affiliation:

1. Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China

2. Institute of Hematology, Zhejiang University, Hangzhou, People’s Republic of China

Funder

973 Program

the Natural Science Foundation of China

Key Project of Science and Technology Department of Zhejiang Province

Publisher

Informa UK Limited

Subject

Hematology,Hematology

Link

https://tandfonline.com/doi/pdf/10.1080/16078454.2018.1549802

Reference29 articles.

1. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia

2. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation

3. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group

4. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

5. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of Relapsed Acute Lymphocytic Leukemia in Adult Patients;Current Treatment Options in Oncology;2024-06-25

2. Revolutionizing cancer treatment: comprehensive insights into immunotherapeutic strategies;Medical Oncology;2024-01-09

3. Safety and efficacy of T-cell-redirecting bispecific antibodies for patients with multiple myeloma: a systematic review and meta-analysis;Cancer Cell International;2023-09-05

4. Challenges and new technologies in adoptive cell therapy;Journal of Hematology & Oncology;2023-08-18

5. A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell–Mediated Immune Response against EGFR-Expressing Tumors;Cancer Immunology Research;2023-06-27